Floatz logo

Olinvacimab

Colorectal Cancer Metastatic

Korean Cancer Study Groupmonoclonal_antibodyPhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

89 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Calcium folinate pentahydrate
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
Cetuximab
Charite University, Berlin, Germany
Phase 4BB

View all 50 →

Same molecule, other indications

Olinvacimab is also rated in:

glioblastomaDormant
B
Indicative ·
57 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →